Revvity (RVTY) is up about 4.95% in the latest session as the market rotates into the name ahead of its next major catalyst: first-quarter 2026 results, which the company said will be released before market open on Tuesday, May 5, 2026, followed by a 7:30 a.m. ET conference call. (news.revvity.com)

With Q1 results a little over two weeks away, traders often reposition into healthcare tools and diagnostics names where results can quickly reset the forward narrative on demand, margins, and full-year guidance. Revvity previously initiated 2026 guidance after reporting Q4/full-year 2025 results (revenue outlook of $2.96–$2.99 billion and adjusted EPS of $5.35–$5.45), leaving May 5 as the next key checkpoint for investors to assess whether trends are tracking above, in-line, or below plan. (nasdaq.com)

In the weeks leading into earnings, Revvity has also stayed active with corporate updates that can keep investor attention elevated. The company recently launched Signals BioDesign, a cloud-native molecular cloning platform that fits into its Signals software ecosystem, and it also disclosed plans to present at major investor conferences in May and June 2026. While neither item is a quarterly earnings release, both can reinforce a “catalyst calendar” that attracts incremental buying into the print. (stocktitan.net)